Cancer and Risk of COVID-19 Through a General Community Survey

  1. Karla A. Lee
  2. Wenjie Ma
  3. Daniel R. Sikavi
  4. David A. Drew
  5. Long H. Nguyen
  6. Ruth C. E. Bowyer
  7. M. Jorge Cardoso
  8. Tove Fall
  9. Maxim B. Freidin
  10. Maria Gomez
  11. Mark Graham
  12. Chuan-Guo Guo
  13. Amit D. Joshi
  14. Sohee Kwon
  15. Chun-Han Lo
  16. Mary Ni Lochlainn
  17. Cristina Menni
  18. Benjamin Murray
  19. Raaj Mehta
  20. Mingyang Song
  21. Carole H. Sudre
  22. Veronique Bataille
  23. Thomas Varsavsky
  24. Alessia Visconti
  25. Paul W. Franks
  26. Jonathan Wolf
  27. Claire J. Steves
  28. Sebastien Ourselin
  29. Tim D. Spector
  30. Andrew T. Chan
  31. on behalf of the COPE consortium

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

Individuals with cancer may be at high risk for coronavirus disease 2019 (COVID-19) and adverse outcomes. However, evidence from large population-based studies examining whether cancer and cancer-related therapy exacerbates the risk of COVID-19 infection is still limited. Data were collected from the COVID Symptom Study smartphone application since March 29 through May 8, 2020. Among 23,266 participants with cancer and 1,784,293 without cancer, we documented 10,404 reports of a positive COVID-19 test. Compared with participants without cancer, those living with cancer had a 60% increased risk of a positive COVID-19 test. Among patients with cancer, current treatment with chemotherapy or immunotherapy was associated with a 2.2-fold increased risk of a positive test. The association between cancer and COVID-19 infection was stronger among participants >65 years and males. Future studies are needed to identify subgroups by tumor types and treatment regimens who are particularly at risk for COVID-19 infection and adverse outcomes.

Article activity feed

  1. Version published to 10.1634/theoncologist.2020-0572
  2. ScreenIT

    SciScore for 10.1101/2020.05.20.20103762: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04331509RecruitingCOVID-19 Symptom Tracker

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.05.20.20103762v1 on medRxiv